KD Logo

A Guide To The Risks Of Investing In Mineralys Therapeutics Inc (MLYS)

Mineralys Therapeutics Inc’s recently made public that its Chief Executive Officer Congleton Jon unloaded Company’s shares for reported $0.18 million on Jun 20 ’24. In the deal valued at $11.73 per share,14,940 shares were sold. As a result of this transaction, Congleton Jon now holds 926,958 shares worth roughly $11.16 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Then, Congleton Jon sold 16,607 shares, generating $199,073 in total proceeds. Upon selling the shares at $11.99, the Chief Executive Officer now owns 941,898 shares.

Before that, Congleton Jon sold 17,766 shares. Mineralys Therapeutics Inc shares valued at $217,712 were divested by the Chief Executive Officer at a price of $12.25 per share. As a result of the transaction, Congleton Jon now holds 958,505 shares, worth roughly $11.54 million.

Goldman initiated its Mineralys Therapeutics Inc [MLYS] rating to a Buy in a research note published on April 02, 2024; the price target was $30. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who began to cover the stock in early March with a ‘”an Overweight”‘ rating. Stifel began covering MLYS with “Buy” recommendation on March 07, 2023. Guggenheim started covering the stock on March 07, 2023. It rated MLYS as “a Buy”.

Price Performance Review of MLYS

On Friday, Mineralys Therapeutics Inc [NASDAQ:MLYS] saw its stock jump 2.82% to $12.04. Over the last five days, the stock has lost -5.12%. Mineralys Therapeutics Inc shares have risen nearly 40.00% since the year began. Nevertheless, the stocks have fallen -26.67% over the past one year. While a 52-week high of $17.44 was reached on 02/27/24, a 52-week low of $5.85 was recorded on 01/18/24. SMA at 50 days reached $12.62, while 200 days put it at $10.90. A total of 0.84 million shares were traded, compared to the trading of 0.11 million shares in the previous session.

Levels Of Support And Resistance For MLYS Stock

The 24-hour chart illustrates a support level at 11.86, which if violated will result in even more drops to 11.68. On the upside, there is a resistance level at 12.16. A further resistance level may holdings at 12.29. The Relative Strength Index (RSI) on the 14-day chart is 41.70, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.89, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 75.81%. Stochastics %K at 11.53% indicates the stock is a buying.

The most recent change occurred on March 07, 2023 when Evercore ISI began covering the stock and recommended ‘”an Outperform”‘ rating.

Most Popular